Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>EGFR</i>Mutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung Cancer

13 Jul 2005

Abstract excerpt

To the Editor: Patients with lung cancer who respond to gefitinib have been reported to have somatic mutations consisting of deletions in exon 19 and the L858R mutation in exon 21 of the epidermal ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16014893
DOI: 10.1056/nejm200507143530217

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>EGFR</i>Mutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung CancerPMID 16014893Read ↗

Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibSemantic proximity Read ↗

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.Semantic proximity Read ↗

Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.Semantic proximity Read ↗

Somatic Mutations of<i>EGFR</i>in Colorectal Cancers and GlioblastomasSemantic proximity Read ↗

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).Semantic proximity Read ↗

Responsiveness to Cetuximab without Mutations in<i>EGFR</i>Semantic proximity Read ↗

Absence of <i>EGFR</i> mutation in the kinase domain in common human cancers besides non‐small cell lung cancerSemantic proximity Read ↗

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.Semantic proximity Read ↗

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibSemantic proximity Read ↗

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.Semantic proximity Read ↗

Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.Semantic proximity Read ↗

Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.